Under construction – not a live service
Sign in

NCT06700811TerminatedPhase 1

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Phase 1 Study of Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Source: ClinicalTrials.gov · Last updated 14 Oct 2026

Reason given: The study closed due to recruitment challenges.

Brief summary (registry, in English)

Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for difficult to control seizures, including ES. Because ES are associated with worse developmental and cognitive outcomes if not detected or treated quickly and effectively, this trial aims to test the ketogenic diet to prevent ES in this high-risk population. This trial is a single-center pilot study of 10 infants with suspected or confirmed genetic seizure disorders to establish if the protocol of early ketogenic diet administration and ES evaluation is safe and feasible.

Status (registry)
Terminated
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
1 (actual)
First submitted
12 Nov 2024
Start date
11 Aug 2025
Primary completion date
27 Sept 2026
Lead sponsor
Heather Olson
Diseases
Epilepsy
NCT number
NCT06700811

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Epileptic spams prior to enrollment
  • Ongoing treatment with vigabatrin, ACTH, corticosteroids, topiramate or zonisamide. Other anti-seizure medications are permitted.

Lab values

  • Metabolic diagnosis with targeted treatment (including specific indication for ketogenic diet such as glucose transporter disorder, vitamin dependent epilepsies, and others) or exclusion for the ketogenic diet

Other

  • Tuberous sclerosis complex, trisomy 21 (based on differential response to ES treatment)

Who the study is looking for

  • Plan for initiation of ketogenic diet by clinical team for treatment of epilepsy
  • The clinical team initiating the ketogenic diet agrees that the use of the KetoVie formula is appropriate for the subject, as all study subjects need to receive the same formula
  • Male or female, age 0 to less than 9 months (including neonates per investigator's judgment)
  • Epilepsy onset at less than 6 months of age
  • Abnormal development (any sub score of the Bayley-4 less than 1 standard deviation below the mean) and/or neurologic exam (microcephaly, macrocephaly, strabismus, abnormal vision/CVI, hypotonia, spasticity, dystonia, movement disorder), per investigators judgment
  • Suspected or confirmed genetic diagnosis as a cause for epilepsy
  • Weight adequate to complete required study laboratory testing without exceeding maximum allowable blood draws per draw or in a 30 day period per BCH policy

Age in the registry: 0 days to 9 months · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Boston Children's HospitalBostonUnited StatesUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.